Cardiovascular Journal of Africa: Vol 23 No 2 (March 2012) - page 6

THINGS ARE ABOUT
TO CHANGE IN
ANTICOAGULATION
THERAPY
Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd,407 Pine Ave,Randburg.
Tel: +27 (011) 348 2400 • Fax: +27 (011) 787 3766 • Company Reg.No.1966/008618/07.
BI Ref No.254/2010 (Nov 10)
EVERY DAY IN
SOUTH AFRICA
44
**
PATIENTS WILL HAVE AN
AF
*
RELATED STROKE
1, 2, 3
22
**
OF THEM WILL DIE
WITHIN A YEAR (50 %)
4
90 %
OF STROKE PATIENTS
WITH KNOWN AF WERE
NOT THERAPEUTICALLY
ANTICOAGULATED
4
*AF – Atrial Fibrillation
** Best Estimate
REFERENCES:
1. Stats South-Africa.Stats-Online.P0302 - Mid-year population
estimates.Updated 20 July 2010.Available from:
2. Connor M.Stroke Management in South Africa – Who is responsible?
S Afr Psychiatry Rev 2005; 8:125-126.
3. Marini C,De Santis F,Sacco S,et al.Contribution of atrial fibrillation to
incidence and outcome of ischemic stroke: results from a population-
based study.Stroke 2005; 36:1115-9.
4. Gladstone DJ,Bui E,Fang J,et al.Potentially Preventable Strokes in
High-Risk Patients With Atrial Fibrillation Who Are Not Adequately
Anticoagulated.Stroke 2009;40;235-240.
1,2,3,4,5 7,8,9,10,11,12,13,14,15,16,...80
Powered by FlippingBook